MEI Pharma Acquires Litecoin as Primary Treasury Asset
- MEI Pharma shifts $100M to Litecoin, a crypto first.
- Charlie Lee and GSR lead investment strategy.
- Impact on LTC market and future trading dynamics.
MEI Pharma, a NASDAQ-listed company, acquired 929,548 Litecoins for $100 million as its primary treasury asset, marking a significant move in the crypto market on August 4, 2025.
This acquisition represents the first instance of a U.S.-listed firm using Litecoin as a reserve, indicating bullish institutional sentiment and boosting market liquidity.
MEI Pharma has invested $100 million in Litecoin (LTC) as its primary treasury asset. The occasion highlights a significant shift towards crypto by a Nasdaq-listed company, facilitated by influential leaders in the crypto space.
The acquisition was led by Charlie Lee, Litecoin’s creator, now joining MEI’s board. Major crypto trading firm GSR will manage the treasury, setting a new precedent for U.S.-listed firms regarding crypto reserves.
The substantial investment is expected to increase market stability and liquidity for Litecoin. Market dynamics show a price appreciation from $107.58 to $124 per LTC, boosting MEI’s asset value to an estimated $110–$115 million.
Market analysts observe potential for increased institutional interest in Litecoin as a reserve currency. This could reshape financial strategies in corporate treasuries, differing from previous focuses on Bitcoin or Ethereum.
This initiative might prompt further diversification within corporate strategies, potentially enhancing crypto market adoption. MEI Pharma’s strategy includes hedging against inflation, indicating a broader movement within financial circles toward crypto assets.
Historically, LTC purchases have lacked the mainstream corporate adoption seen with Bitcoin. Yet, if it follows Bitcoin’s trajectory, it may lead to substantial market gains. Analysts predict potential regulatory evaluation as this strategic shift unfolds.
